The present communication reporls the imprecision, analytical ränge limits, interference by endogeneous serum constituents and accuracy of the uric acid paminophenazone test, and compares them with those of an HPLC method of established accuracy.
Materials and Methode

Analytical procedures
The Boehringer Mannheim uric acid /?-aminophenazone test kit for mechanized analyses in serum, plasma and urine (Cat. No. 908 240, Boehringer Mannheim GmbH, FRG) was the subject of this evaluation study. Reagent l contains 0.1 mol/1 potassium phosphate (pH 7.8); 6 g/l poly(ethyleneglycol-alkylether); 9.6 mmol/1 sodium cholate; 24 mmol/1 2,4,6-tribromo-3-hydroxybenzoic acid; > 5 kU/1 ascorbate oxidase 1 ).
The reaction is started by addition of reagent 2 [0.1 mol/1 potassium phosphate, pH 7.8; 60 mmol/1 potassium hexacyanoferrate (II); 0.12 mmol/1 4-aminoantipyrine; > l kU/1 peroxidase For comparison purposes, the Boehringer Mannheim uricase /7-aminophenazone test (Cat. No. 157104, Boehringer Mannheim GmbH, FRG) was used on a SMAC analyser äs described by Klose et ai. (6) .
HPLC was a reverse phase procedure developed by Greiling et al. (8) .
GC/MS measurements of uric acid concentrations were performed äs published by Siekmann (9) in four human serumbased lyophilized sera. In order to prevent degradation of uric acid via urate anion free radical formation (11) , the samples were stored in the dark until analysis.
Imprecision
Pool sera and control sera were analyzed with the uric acid paminophenazone test and the reference method at four different coöcentration levels. Within-series imprecision was derived from 20 measurements at each concentratiön level with fresh sera. Between-day imprecision was determined from measurements over 20 days with deep-frozen human sera and cöntrol sera.
Linearity and analytical ränge limits
A dilution series, prepared by mixing varying amounts of a uric acid-supplemented human serum and the same serum without added uric acid, was used to check the linearity. The lower limit of detection was calculated according to Kaiser (12) , i.e. from the mean plus three S. D. of 20 measurements of the blank.
Accuracy
The accuracy of the new method was investigated äs follows. (D) Using the new method, uric acid was measured in duplicate in a human serum-based reference material (SRM No. 909, National Bureau of Standards) with a certified value for uric acid which was also confirmed· by the HPLC method used in the present study.
(E) The recovery of test-specific target values was measured in duplicate in control sera over a period of 20 days, using the new method. The test-specific target values were established with a reference standardization in three independent laboratories using HPLC (8) . The data obtained by each laboratory for each of the respective sera in five independent runs and duplicate measurements were used for the assignment of target values.
Interference
Interference by haemoglobin was evaluated by adding increasing amounts of erythrocyte lysates to aliquots of pooled serum.
The haemoglobin concentrations were quantified with a cyanmethaemoglobin method (Cat. No. 124729, Boehringer Mannheim GmbH, FRG).
We used two methods to examine the effect of bilirubin on the uric acid /?-aminophenazone reagent: the new method was applied to a series of specimens with added crystalline bilirubin, and to icteric sera containing up to 461 μηιοΐ/ΐ native bilirubin; the same samples were also analysed with the HPLC method. A total of 34 pharmaceuticals (see tab. 1) was tested in vitro according to I.e. (13) .
Potential interference by ascorbic acid was investigated with a series of concentrations prepared by mixing aliquots of an ascorbic acid-supplemented serum pool (5.68 mmol/1) with variable amounts of the same serum without ascorbic acid. For these studies we used deep-frozen human sera.
Statistics Regression was analysed s described by Passing & Bablok (14) .
Results
Imprecision
The CV values obtained with the uric acid /?-aminophenazone test did not exceed 1.2% and 2.5% for within-run and between-run imprecisipn, respectively (tab. 2). The imprecision study conducted with HPLC s the reference method revealed a within-run variability of about 0.5% CV and between-run imprecision CVs in the r nge of 0.5% to 0.8% (tab. 3). Analytical r nge limits, linearity
The lower detection limit of the enzymic uric acid test, determined according to Kaiser (12) , was found to be practically zero. This value was confirmed by measuring the dose-response relationship in a series of aqueous Solutions at uric acid concentrations of zero to 60 μηιοΐ/ΐ (data not shown).
The dynamic r nge of linearity of the enzymic test was assessed by using human serum containing varying amounts of added uric acid. Within the tested concentration r nge, which extended up to 1428 μπιοΐ/ΐ, the method was found to be linear ( fig. 2 ).
Interferences
The usual anticoagulant concentrations (100 g/l NaF, 10 g/l EDTA, 100 · 10 3 U/l heparin, 50 g/l citrate) do not influence the test results with the enzymic reagent.
Turbidity caused by lipaemia did not interfere in the enzymic uric acid test, s demonstrated by the failure of 10 g/l added Intralipid® to produce aberrant values.
Up to 186 μπιοΐ/ΐ haemoglobin, haemolysis causes no noticeable interference in the new enzymic test.
Studies on interference by bilirubin were equivocal. Addition of commercial bilirubin to human serum led to a proportional decrease in the apparent uric acid concentration. When 427 μιηοΐ/ΐ crystalline bilirubin was added to serum containing uric acid in the normal r nge, the resulting decrease in the apparent uric acid concentration was approximately 60%.
When we compared the uric acid recovery of the enzymic method with that of HPLC in native icteric sera, we also invariably observed decreased apparent uric acid concentrations. In this case, however decrease was markedly smaller and, furthermore, it depended on the particular serum sample. For example, with an icteric specimen containing 461 μιηοΐ/l bilirubin we found a 22% deviation from the Value obtained with HPLC; on the other hand, other serum specimens with 137 -171 μιηοΐ/ΐ bilirubin, showed no significant interference.
Of the 34 drugs tested, only calcium d besilate, o> methyldopa and noramidopyrine interfered with the present uric acid /^aminophenazone test at therapeut ic concentrations. Calcium d besilate at 100 mg/1, amethyldopa at 100 mg/1 and noramidopyrine at 20 mg/1 caused apparent decreases in the uric acid concentration of about 50, 10 and 11%, respectively.
Ascorbic acid does not cause errone usly low results, until its concentration exceeds 1.14 mmol/1.
Accur cy
As shown in figure 3 , recovery from c ntrol sera with the /7-aminophenazone reagent is 4-10% lower than with GC/MS and HPLC.
The recovery of test-specific target values with the new test in four different c ntrol sera was found to vary from 99.5 to 102.6% (tab. 4). Additionally, we examined the recovery with this colour test in the aqueous primary Standard used for HPLC calibration and a human serum-based reference material. These measurements resulted in 100.3% and 99.9% recoveries of the respective target values (aqueous primary Standard: 384 μηιοΐ/ΐ; human serum-based control material: 483 μιηοΐ/ΐ).
For method comparison, we analysed human serum and urine samples with the proposed method and HPLC. Furthermore, the uric acid /j-amin phenazone test was compared with the uricase/7-aminophenazone method on the SMAC analyser in human sera. We found the present test (y) to agree well with HPLC (x) in both human serum (y = 0.30 + 0.97x; r = 0.995) and urine (y = 2.00 + 1.03x; r = 0.989) ( fig. 4, 5) . A similar good agreement exists between the proposed method (y) and the uricase /j-aminophenazone test (x) on the SMAC analyser (y =5 -0.05 + l.OOx; r = 0.981, flg. 6). 
Discussion
We evaluated an enzymic reagent for the determination of uric acid in serum and urine which utilizes a modified Trinder chromogenic system. The phenolic compound used couples oxidatively with /?-aminophenazone, forming a quinone imine dye with improved molar absorbance. Hence, the sample/reagent ratio in our assay could be kept low, thus reducing possible interference by sample constituents to a minimuin, while retaining satisfactory sensitivity and precision.
Optimization of component concentrations and assay pH ensured completion of colour development within 5 min at 25 °C or 37 °C, and a dynamic measuring r nge extending from zero concentration up to a level probably exceeding the highest level tested in this study which was 1428 μιηοΐ/ΐ. Because of the short incubation times required for preincubation and maximum colour development, this assay can be conveniently adapted to mechanised Systems which are capable of pipetting a Start reagent.
In order to overcome the well known interference of ascorbic acid in Trinder chromogenic Systems, a preincubation step has been included in this new assay during which any ascorbic acid is destroyed by ascorbate oxidase. The ascorbate degrading capacity in our assay is sufficient to eliminate ascorbate concentrations greater than l mmol/1 within 5 min,
Interference by the turbidity of lipaemic sera was avoided in our test by addition of detergent to the preincubation solution, which proved to be effective at least up to ^concentration of 10 g/l added lipid, being equivalent to about 28.6 mmol/1 triacylglycerols (15).
Interference by bilirubin due to chemical and simple spectral effects has been reported for several peroxidase-coupled enzymic colour tests (16) . When we measured uric acid concentrations with the new enzymic /7-aminophenazone reagent in native icteric sera, however, we consistently observed significantly decreased recoveries of HPLC-defined analyte concentrations only when the bilirubin concentration was above 170 μτηοΐ/ΐ. An explanation of this finding may be that the different bilirubin species contained in the individual pathological sera (17) have a different capacity for interference with the assay. Support of this view comes from data obtained recently with an enzymic creatinine /?-aminophenazone method (18) . In these studies, Guder et al. found variable relationship between assay interference and the bilirubin content of icteric sera, and significant disturbance was not detected up to 120 μιηοΐ/ΐ bilirubin.
In the analysis of human serum and urine samples, s well s aqueous primary Standard solution and human serum-based reference material with the enzymic /7-aminophenazone method, we obtained results agreeing closely with those attained with HPLC, which has been proposed s reference method for uric acid determination (19) . In control sera, on the other hand, the enzymic test yielded somewhat lower values compared with HPLC. Therefore, it will be essential to define specific target val es in c ntf l material for the /7-aminophenazone method.
In conclusion, the enzymic pirocedure evaluated in this study is considered to be a reliable method for routine uric acid determinations. Only samples with uncommonly high bilirubin levels, and specimens from patients receiving calcium dobesilate, a-methyldopa and noramidopyrine may give poof assay reŝ ults by the proposed method. In such cases analyses should be run with a method known to be insensitive to these interferences.
